SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-028002
Filing Date
2024-03-29
Accepted
2024-03-29 16:30:06
Documents
8
Period of Report
2024-03-29

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0202592-6k_enlivex.htm 6-K 11140
2 THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS OF ENLIVEX AS OF DECEMBER 31, 2023 ea020259201ex99-1_enlivex.htm EX-99.1 469894
3 CONSENT OF YAREL + PARTNERS ea020259201ex99-2_enlivex.htm EX-99.2 4027
4 GRAPHIC ex99-1_001.jpg GRAPHIC 5652
5 GRAPHIC ex99-1_002.jpg GRAPHIC 31350
6 GRAPHIC image_001.jpg GRAPHIC 4021
7 GRAPHIC image_002.jpg GRAPHIC 6053
8 GRAPHIC image_003.jpg GRAPHIC 5686
  Complete submission text file 0001213900-24-028002.txt   559721
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 24804417
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)